Running semaglutide without tracking labs is flying blind. This guide covers the exact biomarkers to order, optimal ranges, and how to know if Ozempic is actually working.
Quick Summary - Semaglutide drives significant metabolic changes that only blood work can confirm - ApoB, HbA1c, fasting glucose, and liver enzymes are the four non-negotiable markers - Most patients see measurable lab improvements within 12 weeks at therapeutic dose - IGF-1 should be monitored if combining with GH peptides -- semaglutide can modestly suppress it - Draw labs fasted, morning, 48+ hours after your weekly injection for the most stable baseline
You have been on semaglutide for 12 weeks. You feel less hungry. You have lost some weight. Your clothes fit differently.
But do you know what happened to your ApoB? Your fasting insulin? Your liver enzymes? Your cardiovascular risk?
Most semaglutide users have no idea. They weigh themselves, they track their appetite, and they assume the rest is following. Sometimes it is. Sometimes it is not.
Semaglutide is one of the most metabolically active compounds prescribed in the US right now. It does not just suppress appetite. It changes how your liver processes lipids, how your pancreas secretes insulin, how your cardiovascular risk profile looks. These are measurable changes. They show up in your blood before they show up anywhere else.
This guide covers exactly what to order, when to draw it, what optimal looks like, and what to watch for at each stage of treatment.
GLP-1 receptor agonists work through several overlapping mechanisms that directly affect your blood markers.
Insulin secretion modulation. Semaglutide enhances glucose-dependent insulin secretion. Your pancreas gets better at releasing insulin when glucose is actually elevated -- and stops over-releasing it when it is not. The result: fasting glucose and HbA1c improve in most users.
Gastric emptying delay. Slower stomach emptying means slower glucose absorption after meals. This blunts postprandial glucose spikes, which has downstream effects on insulin resistance markers.
Hepatic glucose production. Semaglutide reduces glucose output from the liver -- particularly important in users with fatty liver or early insulin resistance.
Lipid metabolism. Visceral fat is a major driver of dyslipidemia. As semaglutide reduces visceral adipose tissue, lipid profiles improve. ApoB typically falls. Triglycerides improve dramatically in most users.
Liver inflammation. Non-alcoholic fatty liver disease and NASH both improve significantly with GLP-1 therapy. Liver enzymes fall as hepatic fat resolves.
All of these changes are measurable. All of them should be tracked.
These are the markers every semaglutide user should track, ordered by clinical priority.
Tier 1 -- Non-Negotiable (order at baseline and every 12 weeks)
ApoB: Research reference range under 80 mg/dL. Standard lab range under 130 mg/dL. The best single cardiovascular risk predictor -- tracks atherogenic particles directly. Most standard panels skip it. Order it specifically.
HbA1c: Research reference range 4.2 to 5.2 percent. Standard lab range under 5.7 percent. Your 3-month average glucose -- the primary metabolic outcome marker for semaglutide.
Fasting Glucose: Research reference range 70 to 90 mg/dL. Standard lab range 70 to 99 mg/dL. Direct insulin sensitivity signal. Draw after 8 or more hours fasted, morning only.
ALT (liver enzyme): Research reference under 25 U/L for men, under 20 U/L for women. Standard lab under 40 U/L. Semaglutide resolves fatty liver -- watch this fall over time. One of the most telling markers of internal progress.
Triglycerides: Research reference under 100 mg/dL. Standard lab under 150 mg/dL. Responds dramatically to GLP-1 -- often the first marker to improve. A triglyceride drop of 20 to 40 percent is common at 12 weeks.
Tier 2 -- Strongly Recommended (order at baseline and every 6 months)
Fasting Insulin: Research reference 3 to 8 uIU/mL. Catches insulin resistance earlier than HbA1c alone. Most panels skip it -- order it specifically alongside fasting glucose.
hs-CRP: Research reference under 1.0 mg/L. Systemic inflammation -- falls as visceral fat decreases. Useful for tracking BPC-157 anti-inflammatory effect if combining compounds.
HDL-C: Should improve with weight loss and visceral fat reduction. Target above 50 mg/dL for women, above 40 mg/dL for men.
AST and GGT: Additional liver markers -- track alongside ALT. GGT is particularly sensitive to alcohol and fatty liver.
eGFR and Creatinine: Kidney function -- important with significant weight loss and fluid shifts. eGFR above 60 is target.
Electrolytes (sodium, potassium, magnesium): Weight loss and reduced food intake can affect electrolyte balance, particularly in users losing more than 20 pounds.
Tier 3 -- Add If Combining With Other Protocols
IGF-1: Add if using any GH peptide alongside semaglutide. GH peptides and GLP-1 have modest interaction on glucose -- track IGF-1 at 6 and 12 weeks.
Total and Free Testosterone: Significant weight loss affects SHBG and testosterone availability. Add if running any HPG axis support.
Thyroid (TSH, free T3, T4): Metabolic rate changes with significant weight loss can affect thyroid hormone requirements.
Vitamin B12: GLP-1 reduces appetite and food volume -- B12 deficiency can develop with prolonged reduced intake.
Timing is not optional. Drawing at the wrong time gives you misleading data.
At baseline (before starting or within the first week)
Order the complete Tier 1 and Tier 2 panel. This is your before. Without a documented baseline, you cannot measure what semaglutide actually did. This draw is non-negotiable.
At 6 to 8 weeks -- first check-in
HbA1c, fasting glucose, and liver enzymes. This early draw catches any unexpected responses before they compound over months.
At 12 weeks -- primary assessment
Full Tier 1 panel. ApoB should be moving. Triglycerides should be down. Liver enzymes should be trending toward normal. HbA1c should reflect the metabolic shift.
At 6 months -- comprehensive review
Full Tier 1 and Tier 2. By this point you are at or near therapeutic dose. This draw tells you the full metabolic story of your protocol.
Day-of draw: fasted, morning, 48 or more hours after your weekly injection
Semaglutide is weekly. Drawing labs within 24 to 36 hours of injection catches peak drug effect, which can skew fasting glucose slightly. Draw 48 hours or more after injection for the most stable baseline reading.
Enter your baseline ApoB, HbA1c, fasting glucose, and liver enzymes. Log your semaglutide dose alongside each lab draw. StackAI reads your full panel in context of your protocol and shows you whether your markers are tracking the expected trajectory.
Free to start. No credit card. Upload your PDF from Quest, LabCorp, or Function Health and StackAI extracts your values automatically.
Start tracking your semaglutide labs free at myprotocolstack.com/auth/login
Based on clinical trial data and real-world protocol tracking, here is what measurable improvement looks like at 3 months on therapeutic semaglutide dose.
ApoB: Reduction of 8 to 15 mg/dL in most users. Some see larger reductions depending on baseline and dietary changes.
HbA1c: Reduction of 0.5 to 1.5 percentage points in users with elevated baseline. Users starting below 5.5 percent may see minimal change.
Fasting Glucose: Drop of 5 to 15 mg/dL toward optimal range. Often the first marker to show movement.
Triglycerides: Frequently the most dramatic change -- reductions of 20 to 40 percent are common. This reflects both GLP-1 direct effect on hepatic lipid output and visceral fat reduction.
ALT: If elevated at baseline (suggesting fatty liver), expect 20 to 40 percent reduction at 12 weeks with continued improvement through 6 months.
If your markers are not moving in this direction by week 12, it is worth investigating. Common causes: dose too low, injection technique issues, food composition not aligned with GLP-1 mechanism, or a concurrent metabolic condition that needs evaluation.
Semaglutide is remarkable. It is not magic. These are the markers that do not reliably improve -- or that require specific attention.
LDL-C. Semaglutide modestly improves LDL in most users, but the effect is smaller than the triglyceride effect. If LDL-C is significantly elevated, semaglutide alone is not a sufficient cardiovascular intervention. ApoB gives the more important signal.
Muscle mass. This is the most underappreciated risk of rapid GLP-1-driven weight loss. Without deliberate resistance training and adequate protein intake, a significant portion of weight loss can come from lean mass rather than fat. Track body composition -- not just scale weight.
Thyroid. There is no direct GLP-1 effect on thyroid function, but significant weight loss changes metabolic rate, which affects thyroid hormone requirements. If on levothyroxine or with subclinical thyroid issues, recheck thyroid panel at 6 months.
Semaglutide + BPC-157
BPC-157 counteracts GLP-1 nausea through nitric oxide and dopaminergic pathways. No significant lab interactions. Monitor the same markers above.
Semaglutide + Tesamorelin or GH Peptides
GH peptides can modestly raise fasting glucose. Semaglutide improves fasting glucose. The effects partially offset. Monitor fasting glucose and HbA1c at every 8-week draw. Add IGF-1 to your panel when combining these compounds.
Semaglutide + Enclomiphene or Testosterone Support
Significant weight loss with semaglutide raises SHBG, which can lower free testosterone even as total testosterone holds steady. Add free testosterone and SHBG to your monitoring panel if running any HPG axis support.
Semaglutide + Omega-3s
Omega-3 supplementation has additive triglyceride-lowering effects. If triglycerides are elevated at baseline, 3 to 4g EPA+DHA daily alongside semaglutide can produce faster and more significant improvement than either alone.
1. Skipping the baseline draw
Starting semaglutide without a pre-treatment lab panel means you will never know what actually changed. Order labs before your first dose or within the first week.
2. Drawing labs within 24 hours of injection
Weekly semaglutide creates a brief peak in drug effect around 24 to 48 hours post-injection. Draw 48 or more hours after your weekly shot for the most accurate baseline reflection.
3. Tracking weight but not ApoB
Scale weight tells you about pounds. ApoB tells you about cardiovascular risk. The point of treating metabolic disease is reducing cardiovascular risk -- weight is a proxy, ApoB is the target.
4. Not adding liver enzymes
Fatty liver is present in an estimated 30 to 40 percent of overweight adults and is often entirely asymptomatic. Semaglutide consistently improves it. Tracking ALT is one of the clearest ways to confirm the protocol is working inside your liver, not just on your waistline.
5. Stopping monitoring after hitting goal weight
The metabolic changes from semaglutide continue as long as treatment continues. Ongoing quarterly monitoring is standard of care. Hitting a weight goal is not permission to stop watching your numbers.
What blood tests should I get before starting semaglutide?
At minimum: ApoB, HbA1c, fasting glucose, complete metabolic panel (includes liver enzymes and kidney function), and a lipid panel. If combining with other protocols, add IGF-1, testosterone panel, and thyroid. This baseline panel is your before-picture -- every subsequent draw is compared against it.
How long does it take for semaglutide to improve lab values?
Fasting glucose typically improves within 4 to 6 weeks of reaching therapeutic dose. HbA1c reflects 3-month average glucose, so meaningful changes appear at the 12-week draw. ApoB and triglycerides typically show measurable improvement by 12 weeks, with continued improvement through 6 months as visceral fat decreases.
Should I get bloodwork on Ozempic even if I am not diabetic?
Yes. The metabolic effects of semaglutide are not limited to diabetics. ApoB improvement, liver enzyme normalization, and triglyceride reduction occur regardless of baseline glucose status. Non-diabetic users on Ozempic or Wegovy for weight management benefit from the same monitoring protocol.
Does semaglutide affect testosterone levels?
Not directly. However, significant weight loss raises SHBG, which binds testosterone and reduces the free fraction. Men who lose 30 or more pounds on semaglutide sometimes experience a transient drop in free testosterone despite stable total testosterone. Add free testosterone and SHBG to your panel if experiencing symptoms.
Can I upload my Quest or LabCorp results to MyProtocolStack?
Yes. MyProtocolStack accepts PDF lab reports from Quest, LabCorp, Function Health, Marek Health, Rythm Health, and most major US labs. Upload your PDF and the platform automatically extracts your values and maps them to tracked markers. StackAI then analyzes your full panel in context of your semaglutide protocol.
The information in this article is provided for general educational purposes only. It does not constitute medical advice, diagnosis, or treatment. The biomarker ranges referenced are research reference ranges drawn from published literature and are not equivalent to clinical diagnostic criteria. Always consult a licensed healthcare provider before making changes to your health regimen or interpreting your laboratory results. Semaglutide is an FDA-approved prescription medication -- use only under the supervision of a licensed prescriber.
Written by Ryan -- Founder, MyProtocolStack. Last Updated: April 2026.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →